Author details

Full Name

Paul A Goepfert

Affiliation

ORCID

Career Start Year

1995

Papers

176

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37036397	Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.	Clin Infect Dis	2023
36348617	Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.	Journal of Infectious Diseases	2023
37561027	Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.	J Infect Dis	2023
37034641	Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.	medRxiv	2023
37205592	Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial.	Res Sq	2023
37398105	Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.	Res Sq	2023
36958335	A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans.	Immunity	2023
37385888	Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.		2023
37384638	Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.		2023
37440227	Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.		2023
36689221	Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials.	JAMA Netw Open	2023
36920790	Circulating SARS-CoV-2+ megakaryocytes are associated with severe viral infection in COVID-19.	Blood Adv	2023
36787249	Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.		2023
35139271	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.	New England Journal of Medicine	2022
36179551	Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens.	EBioMedicine	2022
36357712	Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.	Nat Microbiol	2022
35898343	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses.	medRxiv	2022
35441174	Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial.	medRxiv	2022
35429381	Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.	Journal of Infectious Diseases	2022
36000845	HLA-II-Associated HIV-1 Adaptation Decreases CD4<sup>+</sup> T-Cell Responses in HIV-1 Vaccine Recipients.	J Virol	2022
35928347	COVID-19 Vaccination and Remdesivir are Associated With Protection From New or Increased Levels of Donor-Specific Antibodies Among Kidney Transplant Recipients Hospitalized With COVID-19.	Transpl Int	2022
35862475	Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody.	PLoS Pathog	2022
36406860	Skewed fate and hematopoiesis of CD34 HSPCs in umbilical cord blood amid the COVID-19 pandemic.	iScience	2022
35465983	Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.	Vaccine	2022
36597532	SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia.		2022
35291292	Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody.	bioRxiv	2022
35035955	Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate.	Clinical and Translational Immunology	2022
35174857	Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies.	Protein Engineering, Design and Selection	2022
34764960	Cross-Reactivity to Mutated Viral Immune Targets Can Influence CD8 T Cell Functionality: An Alternative Viral Adaptation Strategy.	Frontiers in Immunology	2021
34076482	Elevated HIV Infection of CD4 T Cells in MRKAd5 Vaccine Recipients Due to CD8 T Cells Targeting Adapted Epitopes.	Journal of Virology	2021
33859204	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans.	NPJ Vaccines	2021
34229888	AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.	Vaccine	2021
34228645	HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural infection.	Journal of Clinical Investigation	2021
34270631	SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence.	PLoS Pathogens	2021
33887209	Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.	Lancet Infect Dis	2021
33882225	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.	New England Journal of Medicine	2021
34143754	Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses.	JCI insight	2021
34193339	Predictors of Nonseroconversion after SARS-CoV-2 Infection.	Emerg Infect Dis	2021
33649747	Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.	Cell Rep Med	2021
33306283	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.	N Engl J Med	2021
33119547	Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection.	Journal of Clinical Investigation	2021
33052359	SARS-CoV-2-specific peripheral T follicular helper cells correlate with neutralizing antibodies and increase during convalescence.		2020
31911030	Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals.	Vaccine	2020
31645444	Cross-Reactive CD8 T-Cell Responses Elicited by Adenovirus Type 5-Based HIV-1 Vaccines Contributed to Early Viral Evolution in Vaccine Recipients Who Became Infected.	Journal of Virology	2020
32461316	Better Viral Control despite Higher CD4[+] T Cell Activation during Acute HIV-1 Infection in Zambian Women Is Linked to the Sex Hormone Estradiol.	J Virol	2020
32459123	Mechanistic inferences from clinical reports of SARS-CoV-2.	Infectious Diseases	2020
33521696	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.	Cell Rep Med	2020
32747654	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature.	Sci Rep	2020
32787704	Reply to Jakovac and to Rocha et al.: Can vitamin D prevent or manage COVID-19 illness?	Am J Physiol Endocrinol Metab	2020
32620560	TOX is expressed by exhausted and polyfunctional human effector memory CD8 T cells.	Science immunology	2020